News ReleaseView printer-friendly version << Back
DSUVIA Efficacy and Safety Data to be Presented at the American Society of Anesthesiologists (ASA) Annual Conference
Included in this presentation are results from two randomized and placebo-controlled studies in post-operative patients following bunionectomy (SAP202) and abdominal surgery (SAP301). Two studies were open-label and single-arm intended to evaluate sufentanil sublingual tablet 30 mcg (DSUVIA™) in the emergency department (SAP302) and in older, post-operative patients, many with comorbidities (SAP303). Statistically significant SPID12 differences were observed in favor of DSUVIA compared to placebo. Nausea was the most commonly reported AE across all surgery subgroups.
"Pain is the most common reason for delayed discharge from outpatient surgery centers and the main reason for unanticipated hospital admissions," said Dr.
The data will be presented at the American Society of Anesthesiologists ANESTHESIOLOGY® 2018 Annual Meeting,
Details on the Poster Presentation is as follows:
Title: Efficacy and Integrated Safety Results of the Sufentanil Sublingual Tablet 30 mcg by Procedure Type for Management of Moderate to Severe Acute Pain
Date & Time:
Location: Moscone Center, North Hall D, Area B, Monitor 6
For additional information about AcelRx, please visit www.acelrx.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/dsuvia-efficacy-and-safety-data-to-be-presented-at-the-american-society-of-anesthesiologists-asa-annual-conference-300730818.html
Media Contacts: Theresa Dolge, Evoke, 215-928-2748, firstname.lastname@example.org, OR Jessica Ross, Evoke, 215-928-2346, email@example.com, OR Investor Contacts: Raffi Asadorian, CFO, AcelRx, firstname.lastname@example.org, OR Brian Korb, Solebury Trout, 646-378-2923, email@example.com